, Volume 195, Issue 1, pp 1–8 | Cite as

Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review

  • Shalvaree Vaidya
  • Clare L. Hibbert
  • Elizabeth Kinter
  • Stefan Boes



Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.


We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.


The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.


More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.


Idiopathic pulmonary fibrosis Cost Economic impact Systematic review Cost triggers Financial burden 



This research paper is made possible by the help, support, and funding from all those at Biogen International. The paper was written as the Master’s thesis for Shalvaree Vaidya and undertaken during her internship at Biogen.

Compliance with Ethical Standards

Conflict of interest



  1. 1.
    Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404CrossRefPubMedGoogle Scholar
  3. 3.
    Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15:829–835CrossRefPubMedGoogle Scholar
  4. 4.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMedGoogle Scholar
  5. 5.
    Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14:1–12CrossRefGoogle Scholar
  6. 6.
    Lee AS, Mira-Avendano I, Ryu JH, Daniels CE (2014) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 108:955–967CrossRefPubMedGoogle Scholar
  7. 7.
    Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806CrossRefPubMedGoogle Scholar
  8. 8.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3Google Scholar
  10. 10.
    Boccuzzi SJ (2003) Indirect health care costs. In: Weintraub WS (ed) Cardiovascular health care economics. Humana Press, Totowa, NJ, pp 63–79CrossRefGoogle Scholar
  11. 11.
    Statistics, B.o.L. (2015) Consumer price index-all urban consumersGoogle Scholar
  12. 12.
    Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2015) Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12:981–987CrossRefPubMedGoogle Scholar
  13. 13.
    NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, ManchesterGoogle Scholar
  14. 14.
    Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lee JS, McLaughlin S, Collard HR (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17:348–354CrossRefPubMedGoogle Scholar
  16. 16.
    Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The NetherlandsGoogle Scholar
  17. 17.
    Chen SY, Collard HR, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2014) PRS26—an analysis of US medicare beneficiaries: burden of direct medical costs in patients with idiopathic pulmonary fibrosis. Value Health 17:A592CrossRefPubMedGoogle Scholar
  18. 18.
    Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM (2014) Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 32:87–99CrossRefPubMedGoogle Scholar
  19. 19.
    Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB (2015) Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 18:249–257CrossRefPubMedGoogle Scholar
  20. 20.
    George TJ, Arnaoutakis GJ, Shah AS (2011) LUng transplant in idiopathic pulmonary fibrosis. Arch Surg 146:1204–1209CrossRefPubMedGoogle Scholar
  21. 21.
    Cottin V (2013) The impact of emphysema in pulmonary fibrosis. Eur Respir Rev 22:153–157CrossRefPubMedGoogle Scholar
  22. 22.
    Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875–880CrossRefPubMedGoogle Scholar
  23. 23.
    Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 45:253–261CrossRefPubMedGoogle Scholar
  25. 25.
    Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICEGoogle Scholar
  26. 26.
    Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497Google Scholar
  27. 27.
    Hagaman JT, Kinder BW, Eckman MH (2010) Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188:125–132CrossRefPubMedGoogle Scholar
  28. 28.
    Tzouvelekis A, Bonella F, Spagnolo P (2015) Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 11:359–370PubMedPubMedCentralGoogle Scholar
  29. 29.
    Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICEGoogle Scholar
  30. 30.
    Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a yearGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.University of LucerneLucerneSwitzerland
  2. 2.European Market Access, Biogen InternationalZugSwitzerland
  3. 3.LucerneSwitzerland

Personalised recommendations